Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pilot study of interferon gamma for chronic hepatitis C.

Journal of hepatology - 1 Jul 2005

Soza Alejandro, Heller Theo, Ghany Marc, Lutchman Glen, Jake Liang T, Germain June, Hsu Henry H, Park Yoon, Hoofnagle Jay H

Abstract excerpt

BACKGROUND/AIMS: Currently, there are no effective therapies available for patients with chronic hepatitis C who have failed to respond to optimal interferon alfa-based regimens. The aims of this pilot study were to assess the antiviral activity and safety of interferon gamma in chronic hepatitis C. METHODS: Patients with chronic hepatitis C, genotype 1, who had not responded to or who had relapsed after therapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Cell Count
Share to Interferon-alpha
Share to Interferon-gamma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pilot Projects

Share to Recurrence

Share to Ribavirin

Share to Transaminases

Share to Treatment Failure

Source

Identifiers

PMID: 15913831
DOI: 10.1016/j.jhep.2005.02.023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pilot study of interferon gamma for chronic hepatitis C.PMID 15913831Read ↗

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection.Semantic proximity Read ↗

Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial.Semantic proximity Read ↗

Prospective study of a high-intensity interferon-alpha regimen for chronic hepatitis C virus genotype 1b infection.Semantic proximity Read ↗

Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT.Semantic proximity Read ↗

Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial.Semantic proximity Read ↗

Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.Semantic proximity Read ↗

Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response.Semantic proximity Read ↗

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)Semantic proximity Read ↗

Randomized controlled trial of lymphoblastoid interferon alpha for chronic hepatitis C (comparison of 9-MU and 6-MU doses). IFN Treatment Group of Affiliated Hospitals of the Third Department of Internal Medicine at Nagoya University School of Medicine.Semantic proximity Read ↗

Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.Semantic proximity Read ↗

Daily interferon monotherapy for chronic hepatitis C in patients with normal or near-normal serum alanine transaminase levels: a comparison of two protocols.Semantic proximity Read ↗

Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.